Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: CIHR Fellowship

Direct Payment

$150,000.00

Identification of Rare Pathogenic Copy Number Variants in Neurocognitive Disease.

EF 2009-10

Résumé
Autism, developmental delay and schizophrenia (together referred to as neurocognitive disorders) are thought to be the result of individually rare, but collectively common, alterations of specific genes, yet traditional technologies have identified a likely genetic cause for only15-17% of cases. In less than 5% of cases, however, has the association been proven. Initial studies using modern genome screening technologies have begun to identify rare submicroscopic (not identifiable by conventional cytogenetic screening) genomic lesions, but this is complicated by the discovery of significant genetic variations between normal, healthy individuals. Thus, a large number of cases and controls (thousands) will be essential to distinguish disease-causing events from rare, benign variants. To this end I aim to identify genes and copy number variations that cause neurocognitive disorders. This will be accomplished through the application of modern, high resolution whole-genome screening tools to the largest panel of children with developmental disorders studied to date (11,000 controls and 25,000 cases). By utilizing such large, detailed sample sets, we will be able to avoid the challenges that plague conventional studies of rare variants by detecting genomic lesions that are specific to disease in as few as 0.05% of cases. These lesions will be validated in an independent set of 4,525 cases and 2,500 controls by targeted profiling with a clinically transferable method (Illumina BeadXpress). Additionally, we will apply targeted DNA sequencing of the genes we identify in 1,500 cases to identify novel mutations in additional cases. Based on preliminary studies, we anticipate that this project will result in the identification of genetic causes for an additional 5-10% of neurocognitive cases. This will greatly increase our knowledge of intellectual disabilities and the genes affected as well as provide tools for clinical screening and diagnosis..
Programme
CIHR Fellowship
Bénéficiaire
Emplacement
Washington, United States of America
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
203795
Name
Coe Bradley P
Region
Washington
Country
United States of America
Orgtype
Research Institution
Instname2
Genetics
Theme2
Biomedical
Prcname2
Fellowships - Post-PhD
Projecttitle
Identification of Rare Pathogenic Copy Number Variants in Neurocognitive Disease.
Programtype2
Fellowship Programs
Orgnameinp2
Direct Payment
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
CIHR Fellowship
Keyworddelim
Genomics; Neurocognitive Disorders
Abstract
Autism, developmental delay and schizophrenia (together referred to as neurocognitive disorders) are thought to be the result of individually rare, but collectively common, alterations of specific genes, yet traditional technologies have identified a likely genetic cause for only15-17% of cases. In less than 5% of cases, however, has the association been proven. Initial studies using modern genome screening technologies have begun to identify rare submicroscopic (not identifiable by conventional cytogenetic screening) genomic lesions, but this is complicated by the discovery of significant genetic variations between normal, healthy individuals. Thus, a large number of cases and controls (thousands) will be essential to distinguish disease-causing events from rare, benign variants. To this end I aim to identify genes and copy number variations that cause neurocognitive disorders. This will be accomplished through the application of modern, high resolution whole-genome screening tools to the largest panel of children with developmental disorders studied to date (11,000 controls and 25,000 cases). By utilizing such large, detailed sample sets, we will be able to avoid the challenges that plague conventional studies of rare variants by detecting genomic lesions that are specific to disease in as few as 0.05% of cases. These lesions will be validated in an independent set of 4,525 cases and 2,500 controls by targeted profiling with a clinically transferable method (Illumina BeadXpress). Additionally, we will apply targeted DNA sequencing of the genes we identify in 1,500 cases to identify novel mutations in additional cases. Based on preliminary studies, we anticipate that this project will result in the identification of genetic causes for an additional 5-10% of neurocognitive cases. This will greatly increase our knowledge of intellectual disabilities and the genes affected as well as provide tools for clinical screening and diagnosis..
Competitiondate
201002
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Coe, Bradley P
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $150,000~ $0~